Carbon dating cancer: defining the chronology of metastatic progression in colorectal cancer
Colorectal cancer (CRC) is the second most common cancer in Europe and the USA [1]. Synchronous and metachronous metastases contribute to the high mortality of CRC [2] and, despite improvements in the management of metastatic CRC, 5-year mortality remains up to 50% [1, 3, 4] with a worse outcome for synchronous versus metachronous metastasis (5-year relative survival 7.2% versus 17.6%) [2].
Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma
Lung cancer is the leading cause of cancer-related mortality worldwide [1, 2]. Contrast to lung adenocarcinoma [1–3], effective targeted therapy for lung squamous cell carcinoma (LSCC) has remained elusive.
The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting
Despite important advances in new and effective preventative antiemetics, chemotherapy-induced nausea and vomiting (CINV) remains among the most unpleasant and feared side effects of cancer chemotherapy [1, 2].
Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant
Patients receiving chemotherapy as treatment of cancer often experience nausea and vomiting. The acute phase (≤24 h) of chemotherapy-induced nausea and vomiting (CINV) is primarily mediated by 5-hydroxytryptamine (5-HT)3-receptor signaling, whereas the delayed phase (>24–120 h) is primarily mediated by neurokinin (NK)1-receptor signaling [1].
Networking for ovarian rare tumors: a significant breakthrough improving disease management
Rare tumors are defined by an incidence of less than six per 100 000 per year. With an incidence of 16.1/100 000 cases in Europe, the sum of all rare gynecological tumors, including ovarian, fallopian, uterine, cervix, vaginal, and vulvar cancers, represents >50% of all gynecological cancers [1].
Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer
PM01183 (lurbinectedin) is a synthetic tetrahydroisoquinoline that is a selective inhibitor of active transcription. The mechanism involve the irreversible stalling of elongating RNA polymerase II (Pol II) on the DNA template and its specific degradation by the ubiquitin/proteasome machinery, with subsequent DNA breaks and apoptosis [1].
Annals of Oncology now has an Impact Factor of 11.855
Annals of Oncology is the 10th ranking oncology journal out of 217.
To celebrate this increase we have curated a collection of highly cited articles which contributed to this increase.
Why Publish with Annals of Oncology?
Give your research the global platform it deserves; submit to Annals of Oncology, one of the most widely read and cited journals in Oncology.
New goals
Read the article by Editor-in-chief, Jean-Charles Soria on the achievements, scope and future of Annals of Oncology.
ASCO 2017 collection
Explore the Annals of Oncology ASCO article collection, echoing the themes of the 2017 annual meeting.
BioTechnologies
A new series from Annals of Oncology with Associate Editor Elaine Mardis.
Bioinformatics
Bioinformatics: breaking the bottleneck for cancer research. A new series in Annals of Oncology with Associate Editor Nicholas McGranahan.
Industry Corner
Industry corner: perspectives and controversies. A new series in Annals of Oncology with Associate Editor Kapil Dhingra.
